Pharmacokinetics and monte carlo simulations of doripenem in patients with febrile neutropenia;La pharmacocinétique et la pharmacodynamie du doripénème chez les patients neutropéniques fébriles

Annals of Pharmacotherapy

Volumn 46, Issue 10, 2012, Pages 1281-1286

  Stein, Gary E ^a   Kulhanek, Grace ^b   Smith, Curtis L ^c   Kuti, Joseph L ^d   Nicolau, David P ^d   Scharmen, Amy ^b   Farnum, Chris ^e   Tran, Mary Ann ^b   Kalra, Apoorv ^b   Havlichek, Daniel H ^b  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c FERRIS STATE UNIVERSITY   (United States)

^d HARTFORD HOSPITAL   (United States)

^e McLaren Greater Lansing Hospital   (United States)

Author keywords

Doripenem; Neutropenia; Pharmacokinetics

Indexed keywords

DORIPENEM;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CARBAPENEMS; FEMALE; GRAM-NEGATIVE BACTERIA; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MONTE CARLO METHOD; NEUTROPENIA; YOUNG ADULT;

EID: 84867798892     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R097     Document Type: Article

References (24)

1. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Executive summary: clinical practice guideline for the use of antimicrobial agents in neutropenic pa-tients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011;52:427-31.
2. Paterson DL, DePestel DD. Doripenem. Clin Infect Dis 2009;49:291-8.
3. Davies TA, Queenan AM, Morrow BJ, et al. Longitudinal survey of car-bapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-9. J Antimicrob Chemother 2011;66:2298-307.
4. Berthoin K, Le Duff CS, Marchand-Brynaert J, et al. Stability of meropenem and doripenem solutions for administration by continuous infusion. J Antimicrob Chemother 2010;65:1073-5.
5. Samtani MN, Flamm R, Kaniga K, Nandy P. Pharmacokinetic-pharmaco-dynamic-model-guided doripenem dosing in critically ill patients. Anti-microb Agents Chemother 2010;54:2360-4.
6. Cirillo I, Vaccaro N, Turner K, et al. Pharmacokinetics, safety, and tolera-bility of doripenem after 0.5-, 1-, and 4-hour infusions in healthy volun-teers. J Clin Pharmacol 2009;49:798-806.
7. Theuretzbacher U. Pharmacokinetic and pharmacodynamic issues for antimicrobial therapy in patients with cancer. Clin Infect Dis 2012;54: 1785-92.
8. Lortholary O, Lefort A, Tod M, et al. Pharmacodynamics and pharma-cokinetics of antibacterial drugs in the management of febrile neutrope-nia. Lancet Infect Dis 2008;8:612-20.
9. Drusano GL, Plaisance KL, Forrest A, et al. Steady-state pharmacokinet-ics of imipenem in febrile neutropenic cancer patients. Antimicrob Agents Chemother 1987;31:1420-2.
10. Janmohamed RM, Leyland MJ, Farrell I. Pharmacokinetics of imipenem/ cilastatin in neutropenic patients with haematological malignancies. J Antimicrob Chemother 1990;25:407-12.
11. Nhylen A, Ljungberg B, Nilsson-Ehle I. Pharmacokinetics of meropen-em in febrile neutropenic patients. Swedish study group. Eur J Clin Microbiol Infect Dis 1997;16:797-802.
12. Roberts JA, Kirkpatrick CMJ, Lipman J. Monte carlo simulations: maxi-mizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients. J Antimicrob Agents 2011;66:227-31.
13. Sutherland C, Nicolau DP. Development of an HPLC method for the de-termination of doripenem in humans and mouse serum. J Chromatogr B 2007;853:123-6.
14. Kim A, Banevicius MA, Nicolau DP. In vivo pharmacodynamic profil-ing of doripenem against Pseudomonas aeruginosa by simulating human exposures. Antimicrob Agents Chemother 2008;52:2497-502.
15. Spinler SA, Nawarskas JJ, Boyce EG, et al. Predictive performance of ten equations for estimating creatinine clearance in cardiac patients. Ann Pharmacother 1998;32:1275-83.
16. Rahal JJ. Antimicrobial resistance among and therapeutic options against gram-negative pathogens. Clin Infect Dis 2009;49(suppl 1):S4-10.
17. Nicolau DP, Kuti JL. Optimizing antibiotic-related outcomes in the criti-cally ill patient. Infect Dis Clin Prac 2005;13:158-64.
18. Jaruratanasirikul S, Limapichat T, Jullangkoon M, et al. Pharmacody-namics of meropenem in critically ill patients with febrile neutropenia and bacteraemia. Intern J Antimicrob Agents 2011;38:231-6.
19. Lodise TP, Lomaestro BM, Drusano GL. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on β-lactam an-tibiotics. Pharmacotherapy 2006;26:320-32.
20. Vaccaro N, Umeh O, Redman R, Cirillo I. Pharmacokinetics of doripen-em 1 g administered over 4 hours in patients with ventilator-associated pneumonia (abstract A1-018.). In: Abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 12-15, 2009, San Francisco, CA.
21. Nandy P, Samtani MN, Lin R. Population pharmacokinetics of doripen-em based on data from phase 1 studies with healthy volunteers and phase 2 and 3 studies with critically ill patients. Antimicrob Agents Chemother 2010;54:2354-9.
22. Ariano RE, Nyhlen A, Donnelly JP, Sitar DS, Harding GKM, Zelenitsky SA. Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann Pharmacother 2005;39:32-8.doi: 10.1345/aph.1E271
23. Udy AA, Roberts JA, De Waele JJ, et al. What's behind the failure of emerging antibiotics in the critically ill? Intern J Antimicrob Agents 2012;39:455-7.
24. Safdar A, Armstrong D. Infections in patients with hematologic neo-plasms and hematopoietic stem cell transplantation: neutropenia, hu-moral and splenic defects. Clin Infect Dis 2011;53:798-806.